Literature DB >> 12735507

Localized prostate cancer: radiation or surgery?

Eric A Klein1, Patrick A Kupelian.   

Abstract

The treatment of localized prostate cancer remains controversial because of the lack of conclusive well-controlled or randomized studies comparing outcomes of radiotherapy to outcomes of radical prostatectomy. A comparison of different therapies should include issues of cancer control, morbidity, quality of life (QOL), salvage of primary treatment failures, late effects, and cost. The available data suggest that these two modalities provide similar rates of cancer control at 10 years, and that except for the youngest patients, choice of therapy should be based on toxicity and QOL issues.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12735507     DOI: 10.1016/s0094-0143(02)00179-9

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  7 in total

1.  Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody.

Authors:  Tadanobu Nagaya; Yuko Nakamura; Shuhei Okuyama; Fusa Ogata; Yasuhiro Maruoka; Peter L Choyke; Hisataka Kobayashi
Journal:  Mol Cancer Res       Date:  2017-06-06       Impact factor: 5.852

2.  LKB1 suppresses proliferation and invasion of prostate cancer through hedgehog signaling pathway.

Authors:  Peiyuan Xu; Fei Cai; Xiaofei Liu; Lele Guo
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

3.  Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition.

Authors:  Xichun Liu; Ruijuan Gao; Yan Dong; Lifang Gao; Yanying Zhao; Lijuan Zhao; Xuejian Zhao; Haitao Zhang
Journal:  BMC Cancer       Date:  2010-08-10       Impact factor: 4.430

4.  VEGF is associated with the poor survival of patients with prostate cancer: a meta-analysis.

Authors:  Ping Zhan; Ya-Nan Ji; Li-Ke Yu
Journal:  Transl Androl Urol       Date:  2013-06

5.  Anti-tumor effects of a recombinant anti-prostate specific membrane antigen immunotoxin against prostate cancer cells.

Authors:  Ping Meng; Qing-Chuan Dong; Guang-Guo Tan; Wei-Hong Wen; He Wang; Geng Zhang; Yan-Zhu Wang; Yu-Ming Jing; Chen Wang; Wei-Jun Qin; Jian-Lin Yuan
Journal:  BMC Urol       Date:  2017-02-13       Impact factor: 2.264

6.  Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer.

Authors:  Salma Khan; Jessica M S Jutzy; Malyn May A Valenzuela; David Turay; Jonathan R Aspe; Arjun Ashok; Saied Mirshahidi; Dan Mercola; Michael B Lilly; Nathan R Wall
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

7.  3p21.3 tumor suppressor gene RBM5 inhibits growth of human prostate cancer PC-3 cells through apoptosis.

Authors:  Lijing Zhao; Ranwei Li; Chen Shao; Ping Li; Jian Liu; Ke Wang
Journal:  World J Surg Oncol       Date:  2012-11-16       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.